- COMMENT
Digital health technologies in clinical trials for central nervous system drugs: an EU regulatory perspective
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 20, 83-84 (2021)
doi: https://doi.org/10.1038/d41573-020-00168-z
Acknowledgements
Some of this information has been presented at the ECNP meeting in Copenhagen, Denmark, in September 2019 in the context of a joint ECNP/EMA session entitled “Challenges and perspectives with the use of digital technology in psychiatry”. We would like to acknowledge the ECNP and the other panellists (E. M. Pich, G. Pandina and P. Haselager), for allowing necessary and fruitful interactions between stakeholders in the field, notably EMA, FDA, academia, industry and patient representatives.
Disclaimer
The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the EMA or one of its committees or working parties. V.M. carried out this work when she was still in her former position as an employee of the Italian Medicines Agency (AIFA). Her views are personal and may not be understood or quoted as being made on behalf of or reflecting the position of AIFA or EMA or the US FDA.
References
Hsin, H. et al. Transforming psychiatry into data-driven medicine with digital measurement tools. NPJ Digit. Med. 1, 37 (2018).
Goldsack, J. C. et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). NPJ Digit. Med. 3, 55 (2020).
Bakker, J.P. et al. A systematic review of feasibility studies promoting the use of mobile technologies in clinical research. NPJ Digit. Med. 2, 47 (2019).
Haberkamp, M. et al. European regulators' views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials. Neuromuscul. Disord. 29, 514–516 (2019).
Kas M. J. et al. A quantitative approach to neuropsychiatry: The why and the how. Neurosci. Biobehav. Rev. 97, 3–9 (2019).
Competing Interests
C.A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda.
